Venus Remedies expands global presence with marketing authorisation for enoxaparin from Azerbaijan

▴ Venus Remedies
Venus Remedies makes its maiden entry into Azerbaijan’s pharmaceutical market. The company has over a dozen marketing authorisations for enoxaparin worldwide

Chandigarh, December 13, 2023: Venus Remedies Limited, a leading fixed-dosage injectable manufacturer, has reached a significant milestone with a marketing authorisation from Azerbaijan for the first time for enoxaparin, an anticoagulant that plays a crucial role in addressing blood clot formation in patients suffering from deep vein thrombosis, acute coronary syndrome, heart attacks and pulmonary embolism.

This achievement is part of the company’s strategy to tap Azerbaijan’s pharmaceutical market, which has an annual volume of $850 million, and thereby expand into West Asia and neighbouring East European countries. Azerbaijan’s pharmaceutical market is import dominated, with India accounting for 4-5 per cent of the total pharmaceutical imports, ranking sixth among the top exporting countries.

Indian exports account for roughly Rs 500 crore of the $3 billion global enoxaparin market. Having an annual capacity of producing more than five million units of enoxaparin at its robotic line, Venus Remedies is among the largest Indian exporters of this drug.

Enoxaparin, which belongs to the group of medicines known as low molecular weight heparin, prevents existing blood clots from enlarging, facilitates the body's natural clot breakdown processes and prevents the formation of new blood clots.

Mr Saransh Chaudhary, CEO, Venus Medicine Research Centre, commented on this significant achievement, saying, "We are proud to announce the successful marketing authorisation for enoxaparin in Azerbaijan. This regulatory approval highlights our product's bioequivalence to the innovator compound and underscores our commitment towards facilitating global access to essential medications. Enoxaparin has proven to be a crucial drug in managing various medical conditions related to blood clotting, and we are pleased to make it available to patients in Azerbaijan for the first time."

Ms Aditi K. Chaudhary, President, International Business, Venus Remedies, said the company aims to address critical medical needs and improve patient outcomes as a leading player in global healthcare. “The sixth largest exporter of enoxaparin from India, Venus Remedies is also selling this drug in Venezuela, Oman, Spain, Tanzania, Yemen, Uganda and Philippines, among other countries,” she said.

Having secured more than a dozen marketing authorisations for enoxaparin worldwide, Venus Remedies continues to demonstrate its commitment to advancing healthcare solutions that make a meaningful impact on global health.

About Venus Remedies

 

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 70+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. Its manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by European- GMP, WHO-GMP and Latin American GMP (INVIMA), among others. Ranked 107th in Asia and among the world’s 500 largest pharmaceutical manufacturing companies, Venus Remedies has been granted more than 130 patents worldwide and having more than 125 registered trademarks and 25 copyrights for its innovative research products.

 

Tags : #venusremedies #Azerbaijan #pharma #pharmaceutical #marketing #expansion #medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Serum Institute of India Partners with Oxford University to Develop Meningitis-B VaccineApril 18, 2024
Ethical Concerns Arise: Nestlé Accused of Adding Sugar and Honey to Infant Formula and Breakfast Cereals in Low-Income CountriesApril 18, 2024
Empowering India's Youth: IG Drones & AASSC Launch Drone Skill Program, to Upskill 10M YouthApril 17, 2024
Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment TechnologyApril 17, 2024
Top 5 online learning platform for learnersApril 17, 2024
Broad-Spectrum RNA Vaccine Breakthrough for Enhanced Virus ProtectionApril 17, 2024
The Impact of Excessive Internet Usage on School Absence: Finnish Study Reveals Key FindingsApril 17, 2024
Uncovering Delhi's Illegal Fertility Centre Operations: Insights from Recent Child Trafficking CasesApril 17, 2024
CarDekho's CSR Arm Girnar Foundation Hosts Health Check-up Camps for Underprivileged Children in Jaipur and GurugramApril 16, 2024
Atal Incubation Centre – Centre for Cellular and Molecular Biology (AIC-CCMB) signs agreement for placement of equipment with Thermo Fisher Scientific to help advance innovation in India April 16, 2024
AVEKSHA, four-day care centres, for the kids of industrial workers inauguratedApril 16, 2024
Nearly a third of the constituencies have zero women candidates in Phase 1 and 2 of LS Elections; reveals The Quantum Hub’s Factsheet April 16, 2024
Emergency Healthcare Provider Medulance Secures $3 Million Series A Funding Led by Alkemi Growth CapitalApril 16, 2024
The Healing Power of Natural Diversity: How Nature Boosts Mental HealthApril 16, 2024
Unveiling Cellular Recycling: How Nutrient-Starved Cells Adapt to Stressful ConditionsApril 16, 2024
Advancing Cancer Care: AIIMS Bhopal’s Workshop on Biomarker Interpretation in Breast CancerApril 15, 2024
10 Powerful Benefits to Diversify Healthcare Advertising ChannelsApril 15, 2024
Understanding Hospital Sink Contamination: Challenges in Fighting Multidrug-Resistant BacteriaApril 15, 2024
Rajasthan’s Swine Flu Situation: Health Department Observes DeclineApril 15, 2024
Is Your Doctor’s Prescription Incomplete ? Insights from Recent ICMR Study Suggests So!April 13, 2024